Department of Rheumatology, Pellegrin Hospital Center, University Hospital of Bordeaux, Bordeaux, France; Department of Therapeutics, Division of Health, University of Bordeaux, Bordeaux, France.
Clin Pharmacol Ther. 2015 Feb;97(2):122-4. doi: 10.1002/cpt.20. Epub 2014 Dec 15.
Existing analgesics fail to provide adequate pain relief in a significant proportion of patients complaining of chronic pain. Furthermore, their use is limited by tolerability and safety concerns. Thus, there is a huge unmet need for effective and safe innovative painkillers. Considering the major role of nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, the issue is whether anti-NGF biologics under development might offer such an opportunity.
现有的镇痛药在很大一部分抱怨慢性疼痛的患者中无法提供足够的缓解。此外，它们的使用受到耐受性和安全性问题的限制。因此，对于有效和安全的创新止痛药存在巨大的未满足需求。鉴于神经生长因子（NGF）在产生和维持广泛的疼痛状态中起主要作用，问题是正在开发的抗 NGF 生物制剂是否可能提供这样的机会。
